Healthcare
Insulet Corporation(PODD)
Live Price
Offline$145.76
+1.56% today
1Y Change
-52.00%
Window
Jun 23, 2025 โ Jun 16, 2026
- Market Cap
- $12.12B
- Revenue Growth
- +30.7%
- EPS Growth
- -41.2%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Insulet Corporation (PODD) is a Healthcare stock with a market cap of $12.12B and listed on NASDAQ. The stock last traded around $145.76 and down 52.0% across the available one-year price window (Jun 23, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +30.7%, EPS growth of -41.2%, a dividend yield of 0.0%. What stands out right now is revenue +30.7%, EPS -41.2%, free cash flow +23.7% with operating margin 17.5% and ROIC 13.6%. Valuation already assumes a fairly strong business story at P/E 49.8 and price/sales 4.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PODD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+30.7% vs +7.6% peer median
Operating Margin
Near sector median
+17.5% vs +19.4% peer median
P/E
Above sector median
49.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +30.7% and EPS is at -41.2%, with operating margin around 17.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.9% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | +6.0% | -1.6% | -3.2% |
2026 Feb 18, 2026 | +5.4% | -3.5% | -3.9% | -10.8% |
2025 Nov 6, 2025 | +8.8% | -1.1% | +2.9% | -5.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PODD
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PODD Max Drawdown
-59.63%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PODD and SPY.
Company Overview
Insulet Corporation
NASDAQ Global Select
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Leadership
- Ashley A. McEvoy
- IPO Date
- May 15, 2007
- Employees
- 5.4k
- Street Address
- 100 Nagog Park
- Mailing
- Acton, MA, 01720
- Region
- Acton, MA, US
- Reporting Currency
- USD
- Investor Line
- 978 600 7000
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 49.8
- EV/EBITDA
- 25.6
- Price/Sales
- 4.5
- Price/Book
- 8.1
Growth
- Revenue
- +30.7%
- EPS
- -41.2%
- Free Cash Flow
- +23.7%
Profitability
- Gross Margin
- 71.6%
- Operating Margin
- 17.5%
- Net Margin
- 9.1%
- ROE
- 17.4%
- ROIC
- 13.6%
Balance Sheet
- Debt/Equity
- 0.69
- Current Ratio
- 2.78
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.